

Fund Fact Sheet

29 January 2021

GBP Class I Acc
ISIN: IE00BPRBXV28



NAV per Share

GBP Class I Acc £11.79

Fund Particulars

Fund Size £67.8 million
Base Currency US\$
Denominations US\$ / GBP / EUR
Fund Structure Open-ended UCITS
Domicile Dublin, Ireland
Listing Irish Stock Exchange
Launch Date 12 September 2014
Management Polar Capital LLP

Fund Managers



James Douglas

Fund Manager

James has managed the Fund since 2019, he joined Polar Capital in 2015 and has 21 years of industry experience.

Fund Profile

Investment Objective


The Fund aims to achieve long-term capital appreciation by investing in a globally diversified portfolio of healthcare companies.

Key Facts

- Team of 6 sector specialists
- Team with 130+ years of combined industry experience
- Typically 25-40 large-cap stocks
- No benchmark or tracking error constraints
- Fundamentally-driven analysis and stock selection

Share Class Performance

Performance Since Launch (%)



	1 month	3 month	YTD	1 year	3 years	5 years	Since Launch	
							Ann.	Cum.
GBP Class I Acc	0.51	3.97	0.51	7.08	31.29	67.71	10.69	91.40
Index	0.56	7.18	0.56	12.93	41.90	81.45	12.27	109.45

Discrete Annual Performance (%)

12 months to	29.01.21	31.01.20	31.01.19	31.01.18	31.01.17
GBP Class I Acc	7.08	13.98	7.57	7.16	19.20
Index	12.93	14.82	9.44	9.81	16.44

Source: Northern Trust International Fund Administration Services (Ireland) Ltd, monthly percentage growth, GBP and has been calculated to account for the deduction of fees. Fund performance does not take account of any commissions or costs incurred by investors when subscribing for or redeeming shares. The GBP Class I Acc was launched on 12 September 2014. The index performance figures are sourced from Bloomberg and are in GBP terms. These figures refer to the past. Investments in funds are subject to risk. **Past performance is not a reliable indicator of future returns.** The money invested in a fund can increase and decrease in value and past performance is not a reliable indicator that you will get back the full amount invested. The performance calculation is based on GBP. If the currency in which the past performance is displayed differs from the currency of the country in which you reside, then you should be aware that due to exchange rate fluctuations the performance shown may increase or decrease if converted into your local currency. Please see the Important Information on the last page of this document for further information on the risks to your investment.

Polar Capital Funds plc - Healthcare Blue Chip Fund

Portfolio Exposure & Attribution

As at 29 January 2021

Performance Attribution - 1 Month (%)

Top Contributors

Name	Active Weight	Attrib. Effect
Alynlyam Pharmaceuticals	2.05	0.34
Neurocrine Biosciences	2.10	0.29
Sartorius AG	2.02	0.29
Syneos Health	2.64	0.20
Merck & Co	-2.89	0.20


Top Detractors

Name	Active Weight	Attrib. Effect
Abbott Laboratories	-2.75	-0.34
Moderna	-0.48	-0.27
ACADIA Pharmaceuticals	1.90	-0.26
Thermo Fisher Scientific	-2.74	-0.22
Humana	2.38	-0.16

Performance attribution is calculated in US\$ on a relative basis over the month.

Sector Exposure - Top Overweights & Underweights Relative to Index (%)

	Fund (%)	Relative (%)
Healthcare Equipment	22.5	2.3
Biotechnology	17.7	3.8
Pharmaceuticals	17.6	-20.5
Life Sciences Tools & Services	13.1	4.3
Managed Healthcare	12.0	4.9
Healthcare Facilities	4.8	3.4
Healthcare Services	2.9	-0.9
Healthcare Distributors	2.7	1.3
Healthcare Supplies	1.6	-1.1
Healthcare Technology	0.0	-2.6
Cash	5.1	5.1



The column headed "Fund (%)" refers to the percentage of the Fund's assets invested in each sector. The column headed "Relative (%)" refers to the extent to which the Fund is overweight or underweight in each sector compared (relative) to the index.

Top 10 Positions (%)

UnitedHealth Group	6.6
Amgen	4.7
Becton Dickinson	4.3
Medtronic	4.0
AstraZeneca	4.0
Bristol Myers Squibb	4.0
Roche	3.5
Bio-Rad Laboratories	3.5
Sanofi	3.5
Baxter International	3.0

Total 41.1

Total Number of Positions 33

Active Share 75.36%

Market Capitalisation Exposure (%)

Large Cap (>US\$10 billion)	79.6
Mid Cap (US\$5 billion - US\$10 billion)	15.3
Small Cap (<US\$5 billion)	0.0
Cash	5.1

Geographic Exposure (%)

United States	66.0
Germany	7.4
Ireland	4.0
United Kingdom	4.0
Switzerland	3.5
France	3.5
Australia	2.3
Netherlands	2.3
Sweden	1.8
Cash	5.1

Share Class Information

Codes & Fees

Share Class	Bloomberg	ISIN	SEDOL	OCF	Annual Fee
US\$ Class I Acc	PCFIUSA ID	IE00BPRBXQ74	BPRBXQ7	0.99%	0.85%
US\$ Class I Dist	PCFIUSD ID	IE00BPRBXP67	BPRBXP6	0.99%	0.85%
GBP Class I Acc	PCFIGBA ID	IE00BPRBXV28	BPRBXV2	0.99%	0.85%
GBP Class I Dist	PCFIGBD ID	IE00BPRBXT06	BPRBXT0	0.99%	0.85%
EUR Class I Acc	PCFIEUA ID	IE00BPRBXS98	BPRBXS9	0.99%	0.85%
EUR Class I Dist	PCFIEUD ID	IE00BPRBXR81	BPRBXR8	0.99%	0.85%

Minimum Investment: Class I Shares; US\$1 million (or its foreign currency equivalent).

Performance Fee 10.00% of outperformance of MSCI AC World Daily Total Return Net Health Care Index.

Ongoing Charges Figure (OCF) is the latest available, as per the date of this factsheet.

Administrator Details

Northern Trust International Fund
Administration Services (Ireland) Ltd

Telephone +353 1 434 5007

Fax +353 1 542 2889

Dealing Daily

Cut-off 15:00 Dublin time

Note: Totals may not sum due to rounding. It should not be assumed that recommendations made in future will be profitable or will equal performance of the securities in this document. A list of all recommendations made within the immediately preceding 12 months is available upon request.

Polar Capital Funds plc - Healthcare Blue Chip Fund

Fund Managers Comments

As at 29 January 2021

Global equity markets have had an uncertain start to 2021, with healthcare modestly outperforming the broader markets. With both Moderna and Pfizer/BioNTech having set very high bars with their COVID-19 vaccine data late in 2020, the market appears to be less enthusiastic about the recent updates from Johnson & Johnson (JNJ) and Novavax, possibly an unjust assessment. Looking at the healthcare subsectors, life sciences and tools and healthcare services were strong during January whereas managed healthcare and facilities lagged. Pharmaceuticals and biotechnology were both in modest, positive territory. The Fund was up 1% (I US\$ Acc Share Class) in January, broadly in line with the benchmark (MSCI AC World Daily Net TR Health Care Index) which was up 1.04% (in dollar terms) for the month.

The first three weeks of January contained a number of the ingredients that underpin our constructive stance on the healthcare sector as we look at 2021 and beyond, namely companies investing in technologies that drive efficiencies. Here, both Boston Scientific and Hill-Rom are looking to acquire assets that remotely monitor patients' cardiac activity, highlighting the need for early detection and management of cardiac disease. January also witnessed some clinical updates that were well received by the market in the areas of Alzheimer's (Eli Lilly) and polyneuropathy (Alnylam), with the positive COVID-19 vaccine data from JNJ and Novavax coming later in the month.

M&A was also buoyant in January with half a dozen deals announced in the first week alone. Last but not least, the start to the reporting season has been positive with bellwethers United Healthcare, JNJ, Abbott Laboratories and Danaher all reporting strong 2020 earnings with in-line to better guidance for 2021. Unfortunately, the strong start to the year and early enthusiasm was tempered with a marked selloff as we approached the month end. The catalyst for the selloff, we believe, was triggered by the ever-growing influence of retail investors and the decision for pockets of the market to reduce near-term risk exposure via de-grossing.

In terms of material catalysts during the reporting period, Eli Lilly's phase II Alzheimer's data was probably the highlight. Eli Lilly's donanemab, an antibody that targets a modified form of beta amyloid called N3pG, showed a significant slowing of decline in a measure of cognition and daily function in patients with early symptomatic Alzheimer's disease compared to a placebo. In the trial, donanemab slowed decline by 32% relative to the placebo which is a statistically significant outcome. In terms of next steps, Eli Lilly is running another clinical trial but is also in discussion with the US FDA to assess the regulatory path forward. US biotechnology company Alnylam also disclosed positive topline results for its next-generation asset vutrisiran. Vutrisiran, being developed for the treatment of polyneuropathy (a disease where multiple peripheral nerves become damaged), met the primary and all secondary endpoints. A major de-risking event, the update was very well received by the market.

There were also two COVID-19 vaccine updates in the reporting period, from JNJ and Novavax. JNJ's vaccine candidate was 72% effective in the US and 66% effective overall at preventing moderate to severe COVID-19 28 days after vaccination. An underwhelming headline, perhaps, but the vaccine was 85% effective in preventing severe disease and also demonstrated complete protection against COVID-19-related hospitalisation and death. Given the single dose, and the ease of storage (the vaccine candidate is estimated to remain stable for at least three months at temperatures of 2-8°C), then the vaccine could well play an important role in tackling the COVID-19 crisis globally. Novavax also disclosed encouraging results for its vaccine, with 89.3% efficacy in its phase III UK study, with 85.6% efficacy against the UK-variant strain. Novavax also conducted a phase III South African study with the vaccine showing 60% efficacy.

Positive contributors from active positions were Alnylam Pharmaceuticals, Neurocrine Biosciences and Sartorius. Alnylam Pharmaceuticals reacted positively to a clinical update early in the month, as discussed previously. Neurocrine's momentum was in response to a solid set of preliminary financial results, with lead asset Ingrezza (for the treatment of tardive dyskinesia – involuntary, repetitive body movements) showing stability after a challenging period, which was driven by a high percentage of psychiatric practices not taking face-to-face meetings with patients. Life sciences and tools company Sartorius produced another very strong set of operational

results and also updated its long-term guidance, guidance that comfortably exceeded consensus expectations.

Negative contributors from active positions were ACADIA Pharmaceuticals, Humana and Swedish Orphan Biovitrum (SOBI). There were no material updates from US biotech ACADIA during the reporting period, with the stock possibly caught up in the de-grossing momentum. Managed care company Humana actually offered an encouraging update at an investor conference in early January but suffered alongside the managed care group, a group that appears to be very much out of favour at present. SOBI's struggles correlate with downgrades to near-term earnings revisions, with the management team looking to invest in recently acquired or in-licensed pipeline assets.

In terms of portfolio changes, we added positions in Australian healthcare services company Ramsay Health Care and US biotechnology company Biohaven Pharmaceutical. Ramsay Health Care is a leading private hospital operator in Australia, a business that has been adversely impacted by the COVID-19 crisis. With a growing backlog, we believe that surgery volumes could accelerate in the coming months, a scenario that is not necessarily fully reflected in the current valuation. Biohaven Pharmaceutical's recent share price weakness can be attributed to the failure of Alzheimer's asset, tririluzole, in a phase II/III study looking at symptomatic treatment. The primary driver in the equity story, however, is the migraine asset, Nurtec, which is having an excellent launch that is putting upwards pressure on consensus forecasts.

The additions to the portfolio were funded by sales in Chugai Pharmaceuticals and Eli Lilly, both which have enjoyed significant, positive momentum in recent months. Following a marked derating heading into the US elections, Chugai has benefitted from a rapid, post-election rerating as the market digested the positive implications of a Democratic President but a divided Congress. Eli Lilly has also rerated in spectacular fashion following a positive financial update in December 2020, some positive newsflow for its key diabetes asset, tirzepatide, and the previously mentioned Alzheimer's data.

January has been a hugely frustrating month, but one that leaves us with heightened enthusiasm for the healthcare sector given what lies ahead. The frustration comes from the end-of-month selloff following what was a really strong start to the year, both in terms of newsflow and operational momentum. The enthusiasm is borne from the observation that some of the key investment themes we have identified are evident and accelerating. The healthcare industry is continuing to invest in products, technologies and services that will drive efficiencies and coordinate care to yield better outcomes for patients. The pace of innovation is unlikely to slow, and there is strong rationale that M&A will continue to be an important source of growth as companies look to complement their internal assets. Prevention is super-critical, and there is hope that the accelerated investment in diagnostics infrastructure will prove to be valuable once we move past the COVID-19 crisis and healthcare systems start to screen for a wider menu of diseases. With the political landscape in the US also becoming clearer, given the Biden administration is appearing to adopt a more supportive and inclusive philosophy, we think an optimistic stance is the right one.

James Douglas

5 February 2021



©2020 Morningstar. All Rights Reserved. Rating representative of the I USD Acc Share Class, as at 31/12/2020. Ratings may vary between share classes. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results. For more detailed information about the Morningstar Rating or Morningstar Analyst rating, including its methodology, please go to: <http://corporate1.morningstar.com/AnalystRating/>.

It should not be assumed that recommendations made in future will be profitable or will equal performance of the securities in this document. A list of all recommendations made within the immediately preceding 12 months is available upon request.

Polar Capital Funds plc - Healthcare Blue Chip Fund

Important Information

Important Information: This document is provided for the sole use of the intended recipient and is not a financial promotion. Healthcare Blue Chip Fund (the "Fund") is a sub-fund of Polar Capital Funds plc - which is authorised by the Central Bank of Ireland as an Undertaking for Collective Investment in Transferable Securities under the European Communities (Undertakings for Collective Investment in Transferable Securities) Regulations 2011 (S.I. 352/2011), as amended. This document has been prepared by Polar Capital for informational purposes only for the sole use of the intended recipient. It does not seek to make any recommendation to buy or sell any particular security (including shares in the Fund) or to adopt any specific investment strategy. This document does not contain information material to an investor's decision to invest in the Fund. Shares in the Fund are offered only on the basis of information contained in the prospectus, key investor information document ("KIID"), and the latest annual audited accounts. Copies are available free of charge from Polar Capital at the below address or on www.polarcapital.co.uk. The KIID is available in Danish, Dutch, English, French, German, Italian, Norwegian, Spanish and Swedish. The prospectus is available in English.

Regulatory Status: Polar Capital LLP is a limited liability partnership (OC314700), authorised and regulated by the UK Financial Conduct Authority and is registered as an investment adviser with the US Securities & Exchange Commission. A list of members is open to inspection at 16 Palace Street, London, SW1E 5JD. FCA authorised and regulated Investment Managers are expected to write to investors in funds they manage with details of any side letters they have entered into. The FCA considers a side letter to be an arrangement known to the investment manager which can reasonably be expected to provide one investor with more materially favourable rights, than those afforded to other investors. These rights may, for example, include enhanced redemption rights, capacity commitments or the provision of portfolio transparency information which are not generally available. The Fund and the Investment Manager are not aware of, or party to, any such arrangement whereby an investor has any preferential redemption rights. However, in exceptional circumstances, such as where an investor seeds a new fund or expresses a wish to invest in the Fund over time, certain investors have been or may be provided with portfolio transparency information and/or capacity commitments which are not generally available. Investors who have any questions concerning side letters or related arrangements should contact the Polar Capital Desk at the Administrator on (+353) 1 434 5007. The Fund is prepared to instruct the custodian of the Fund, upon request, to make available to investors portfolio custody position balance reports monthly in arrears.

Third-party Data: Some information contained herein has been obtained from third party sources and has not been independently verified by Polar Capital. Neither Polar Capital nor any other party involved in or related to compiling, computing or creating the data makes any express or implied warranties or representations with respect to such data (or the results to be obtained by the use thereof), and all such parties hereby expressly disclaim all warranties of originality, accuracy, completeness, merchantability or fitness for a particular purpose with respect to any data contained herein.

Holdings: Portfolio data is "as at" the date indicated and should not be relied upon as a complete or current listing of the holdings (or top holdings) of the fund. The holdings may represent only a small percentage of the aggregate portfolio holdings, are subject to change without notice, and may not represent current or future portfolio composition. Information on particular holdings may be withheld if it is in the fund's best interest to do so. A historic complete list of the portfolio holdings may be made available upon request. It should not be assumed that recommendations made in future will be profitable or will equal performance of the securities in this document. A list of all recommendations made within the immediately preceding 12 months is available upon request. This document is designed to provide updated information to professional investors to enable them to monitor the Fund. No other persons should rely upon it. The information provided in this document should not be considered a recommendation to purchase or sell any particular security.

Information Subject to Change: The information contained herein is subject to change, without notice, at the discretion of Polar Capital and Polar Capital does not undertake to revise or update this information in any way.

Forecasts: References to future returns are not promises or estimates of actual returns Polar Capital may achieve, and should not be relied upon. The forecasts contained herein are for illustrative purposes only and are not to be relied upon as advice or interpreted as a recommendation. Forecasts are based upon subjective estimates and assumptions about circumstances and events that may not yet have taken place and may never do so.

Statements/Opinions/Views: All opinions and estimates constitute the best judgment of Polar Capital as of the date hereof, but are subject to change without notice, and do not necessarily represent the views of Polar Capital. This material does not constitute legal or accounting advice; readers should contact their legal and accounting professionals for such information. All sources are Polar Capital unless otherwise stated.

Benchmark: The Fund is actively managed and uses the MSCI AC World Daily Total Return Net Health Care Index as a performance target and to calculate the performance fee. The benchmark has been chosen as it is generally considered to be representative of the investment universe in which the Fund invests. The performance of the Fund is likely to differ from the performance of the benchmark as the holdings, weightings and asset allocation will be different. Investors should carefully consider these differences when making comparisons. Further information about the benchmark can be found www.msicbarra.com. The benchmark is provided by an administrator on the European Securities and Markets Authority (ESMA) register of benchmarks which includes details of all authorised, registered, recognised and endorsed EU and third country benchmark administrators together with their national competent authorities.

Performance: The performance shown has been calculated to account for the deduction of fees and expenses and includes the reinvestment of dividends and capital gain distributions. £ or GBP/US\$/JPY/EUR/CHF = Currency abbreviations of: British Pound sterling/US Dollar/Japanese Yen/Euro/Swiss Franc, respectively.

Allocations: The strategy allocation percentages set forth in this document are estimates and actual percentages may vary from time-to-time. The types of investments presented herein will not always have the same comparable risks and returns. Please see the private placement memorandum for a description of the investment allocations as well as the risks associated therewith. Please note that the Fund may elect to invest assets in different investment sectors from those depicted herein, which may entail additional and/or different risks. Performance of the Fund is dependent on the Investment Manager's

ability to identify and access appropriate investments, and balance assets to maximize return to the Fund while minimizing its risk. The actual investments in the Fund may or may not be the same or in the same proportion as those shown herein.

Risk: Factors affecting fund performance may include changes in market conditions (including currency risk) and interest rates, as well as other economic, political, or financial developments. The Fund's investment policy allows for it to enter into derivatives contracts. Leverage may be generated through the use of such financial instruments and investors must be aware that the use of derivatives may expose the Fund to greater risks, including, but not limited to, unanticipated market developments and risks of illiquidity, and is not suitable for all investors. Past performance is not a guide to or indicative of future results. Future returns are not guaranteed and a loss of principal may occur. Polar Capital may also receive a performance fee based on the appreciation in the NAV per share and accordingly the performance fee will increase with regard to unrealised appreciation, as well as realised gains. The performance fee may create an incentive for Polar Capital to make investments for Polar Capital Funds plc which are riskier than would be the case in the absence of a fee based on the performance of Polar Capital Funds plc.

Country Specific Disclaimers: It is the responsibility of any person/s in possession of this document to inform themselves of, and to observe, all applicable laws and regulations of any relevant jurisdiction. Neither Polar Capital nor Polar Capital Funds plc shall be liable for, and accept no liability for, the use or misuse of this document. If such a person considers an investment in Shares of the Fund, they should ensure that they have been properly advised about the suitability of an investment. Please be aware that not every sub-fund of Polar Capital Funds plc or share class is available in all jurisdictions.

Australia: Neither Polar Capital nor Polar Capital Funds plc are registered as a foreign company in Australia. The provision of this document to any person does not constitute an offer of shares of Polar Capital Funds plc to any person or an invitation to any person to apply for shares of Polar Capital Funds plc. Any such offer or invitation will only be extended to a person in Australia if that person is a sophisticated or professional investor for the purposes of section 708 of the Corporations Act 2001 of Australia ("Corporations Act") and a "wholesale client" for the purposes of section 761G of the Corporations Act. This document is not intended to be distributed or passed on, directly or indirectly, to any other class of persons in Australia. This document is not a disclosure document under Chapter 6D of the Corporations Act or a Product Disclosure Statement under Part 7.9 of the Corporations Act. It is not required to, and does not, contain all the information which would be required in a disclosure document or a Product Disclosure Statement. It has not been lodged with the Australian Securities and Investments Commission. Any person to whom shares of Polar Capital Funds plc are issued or sold must not, within 12 months after the issue, offer, transfer or assign those shares to investors in Australia except in circumstances where disclosure to investors is not required under the Corporations Act.

Hong Kong: The Fund is a collective investment scheme as defined in the Securities and Futures Ordinance (Cap. 571) (the "SFO") but is not authorised under Section 104 of the SFO by the Securities and Futures Commission of Hong Kong ("SFC"). This document does not constitute an offer or invitation to the public in Hong Kong to acquire interests in the Fund. In addition, this document has not been approved by the SFC nor has a copy of it been registered with the Registrar of Companies in Hong Kong, and therefore may only be issued or possessed for the purpose of issue to persons who are "professional investors" under the SFO and any rules made under that Ordinance or as otherwise permitted by the SFO.

The Netherlands: This factsheet is for professional client use only in the Netherlands and it is intended that the Fund will only be marketed to professional clients in the Netherlands. Polar Capital Funds plc is authorized to offer shares in the Healthcare Blue Chip Fund to investors in the Netherlands on a cross border basis and is registered as such in the register kept by the Dutch Authority for the Financial Markets ("AFM") www.afm.nl.

Portugal: The Healthcare Blue Chip Fund has been passported into Portuguese jurisdiction pursuant to Directive 65/2009/EU of the European Parliament and of the Council, of 13 July 2009 and Regulation 584/2010, of 1 July 2010, and are registered with the Portuguese Securities Commission (CMVM) for marketing in Portugal.

Spain: The Fund is registered in Spain with the Comisión Nacional del Mercado de Valores ("CNMV") under registration number 771.

Switzerland: The principal fund documents (the prospectus, KIIDs, memorandum and articles of association, annual report and semi-annual report) of the Fund may be obtained free of charge from the Swiss Representative. In respect of the shares distributed in Switzerland, the place of performance and the place of jurisdiction is at the registered office of the Swiss Representative. The Fund is domiciled in Ireland. The Swiss representative and paying agent is BNP Paribas Securities Services, Paris, succursale de Zurich, Selnaustrasse 16, CH-8002 Zurich, Switzerland.

Austria / Denmark (professional only) / Finland / Germany / Ireland / Italy (professional only) / Luxembourg / Norway / Spain / Sweden and the United Kingdom: The Fund is registered for sale to all investors in these countries. Investors should make themselves aware of the relevant financial, legal and tax implications if they choose to invest.